000 | 01191 a2200289 4500 | ||
---|---|---|---|
005 | 20250513161242.0 | ||
264 | 0 | _c19990125 | |
008 | 199901s 0 0 eng d | ||
022 | _a0959-8049 | ||
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aPrior, C | |
245 | 0 | 0 |
_aComments on Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group, van Zandwijk et al., Eur J Cancer 1997, 33, 1759-1766. _h[electronic resource] |
260 |
_bEuropean journal of cancer (Oxford, England : 1990) _cSep 1998 |
||
300 |
_a1638 p. _bdigital |
||
500 | _aPublication Type: Comment; Letter | ||
650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
650 | 0 | 4 |
_aCarcinoma, Small Cell _xtherapy |
650 | 0 | 4 | _aClinical Trials, Phase III as Topic |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aInterferon-gamma _xtherapeutic use |
650 | 0 | 4 |
_aLung Neoplasms _xtherapy |
650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
650 | 0 | 4 | _aRecombinant Proteins |
700 | 1 | _aThaler, J | |
700 | 1 | _aHuber, H | |
773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 34 _gno. 10 _gp. 1638 |
|
999 |
_c9855395 _d9855395 |